OTCPK:TMED

Stock Analysis Report

Executive Summary

Trimedyne, Inc. manufactures and sells lasers, and disposable and reusable fiber-optic laser devices for use in the medical field.

Snowflake

Fundamentals

Adequate balance sheet and fair value.

Share Price & News

How has Trimedyne's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

TMED

-0.4%

US Medical Equipment

1.0%

US Market


1 Year Return

-55.6%

TMED

12.8%

US Medical Equipment

6.7%

US Market

Return vs Industry: TMED underperformed the US Medical Equipment industry which returned 12.8% over the past year.

Return vs Market: TMED underperformed the US Market which returned 6.7% over the past year.


Share holder returns

TMEDIndustryMarket
7 Day0%-0.4%1.0%
30 Day4.2%-2.7%-1.8%
90 Day-3.8%-0.3%-1.8%
1 Year-55.6%-55.6%13.7%12.8%9.1%6.7%
3 Year-9.1%-9.1%70.0%64.8%46.1%36.6%
5 Year-64.3%-64.3%130.9%105.1%66.9%48.6%

Price Volatility Vs. Market

How volatile is Trimedyne's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Trimedyne undervalued based on future cash flows and its price relative to the stock market?

1.97x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Undervalued: Insufficient data to calculate TMED's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate TMED's fair value to establish if it is undervalued.


Price Based on Earnings

PE vs Industry: TMED is good value based on its PE Ratio (2x) compared to the Medical Equipment industry average (40.1x).

PE vs Market: TMED is good value based on its PE Ratio (2x) compared to the US market (17.5x).


Price Based on Expected Growth

Low PEG Ratio: Insufficient data to calculate TMED's PEG Ratio to determine if it is good value.


Price Based on Value of Assets

PB vs Industry: TMED is good value based on its PB Ratio (0.2x) compared to the US Medical Equipment industry average (3.7x).


Next Steps

Future Growth

How is Trimedyne expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Trimedyne has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Trimedyne performed over the past 5 years?

18.6%

Last years revenue growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if TMED's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: TMED has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: TMED has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: TMED's Return on Equity (8.6%) is considered low.


Return on Assets

ROA vs Industry: TMED has a higher Return on Assets than the Medical Equipment industry average last year.


Return on Capital Employed

ROCE Improving: TMED's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is Trimedyne's financial position?


Financial Position Analysis

Short Term Liabilities: TMED's short term assets ($2.5M) exceeds its short term liabilities ($733.0K)

Long Term Liabilities: TMED's short term assets (2.5M) exceeds its long term liabilities (2.0K)


Debt to Equity History and Analysis

Debt Level: TMED's debt to equity ratio (1.8%) is considered satisfactory

Reducing Debt: TMED's debt to equity ratio has increased from 1.3% to 1.8% over the past 5 years.

Debt Coverage: TMED's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: TMED's interest payments on its debt are well covered by EBIT (106.5x coverage).


Balance Sheet

Inventory Level: TMED has a high level of physical assets or inventory.

Debt Coverage by Assets: TMED's debt is covered by short term assets (assets are 52.708330x debt).


Next Steps

Dividend

What is Trimedyne's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage0.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate TMED's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate TMED's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if TMED's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TMED's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TMED's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Trimedyne's salary, the management and board of directors tenure and is there insider trading?

4.8yrs

Average board tenure


CEO

Glenn Yeik (51yo)

4.8yrs

Tenure

US$205,486

Compensation

Mr. Glenn D. Yeik is Chairman, Chief Executive Officer and President at Trimedyne, Inc. He served as the President of Trimedyne, Inc. since September 29, 2003 until September 28, 2016 and served as its Pri ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Glenn's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Glenn's compensation has been consistent with company performance over the past year.


Board Age and Tenure

4.8yrs

Average Tenure

67.5yo

Average Age

Experienced Board: TMED's board of directors are considered experienced (4.8 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Management Team

  • Brian Kenney (62yo)

    Vice President of Global Sales & Marketing

    • Tenure: 19.8yrs
    • Compensation: US$124.31k
  • Glenn Yeik (51yo)

    Chairman

    • Tenure: 4.8yrs
    • Compensation: US$205.49k

Board Members

  • Don Baker (89yo)

    Director

    • Tenure: 36.4yrs
  • Glenn Yeik (51yo)

    Chairman

    • Tenure: 4.8yrs
    • Compensation: US$205.49k
  • Alan Loeb (54yo)

    Director

    • Tenure: 4.8yrs
  • Edward Spriegel (81yo)

    Director

    • Tenure: 4.5yrs

Company Information

Trimedyne, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Trimedyne, Inc.
  • Ticker: TMED
  • Exchange: OTCPK
  • Founded: 1980
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$462.393k
  • Shares outstanding: 123.31k
  • Website: https://www.trimedyne.com

Number of Employees


Location

  • Trimedyne, Inc.
  • 5 Holland
  • Building 223
  • Irvine
  • California
  • 92618
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TMEDOTCPK (Pink Sheets LLC)YesCommon StockUSUSDApr 1982

Biography

Trimedyne, Inc. manufactures and sells lasers, and disposable and reusable fiber-optic laser devices for use in the medical field. It offers lasers, fibers, needles, and switch tips for use in orthopedics, ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 01:28
End of Day Share Price2019/10/04 00:00
Earnings2018/09/30
Annual Earnings2018/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)